<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="117" measure-type="s" measure-number="909" measure-id="id117s909" originChamber="SENATE" orig-publish-date="2021-03-23" update-date="2021-06-22">
<title>Prescription Drug Price Relief Act of 2021</title>
<summary summary-id="id117s909v00" currentChamber="SENATE" update-date="2021-06-22">
<action-date>2021-03-23</action-date>
<action-desc>Introduced in Senate</action-desc>
<summary-text><![CDATA[<p><b>Prescription Drug Price Relief Act of 2021</b></p> <p>This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. </p> <p>Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.</p> <p>Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. </p> <p>The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures. </p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
